

ARTICLE

Genome-wide gene expression profiling of the Angelman syndrome mice with *Ube3a* mutation

Daren Low¹ and Ken-Shiung Chen^{*,1}

Angelman syndrome (AS) is a human neurological disorder caused by lack of maternal *UBE3A* expression in the brain. *UBE3A* is known to function as both an ubiquitin-protein ligase (E3) and a coactivator for steroid receptors. Many ubiquitin targets, as well as interacting partners, of *UBE3A* have been identified. However, the pathogenesis of AS, and how deficiency of maternal *UBE3A* can upset cellular homeostasis, remains vague. In this study, we performed a genome-wide microarray analysis on the maternal *Ube3a*-deficient (*Ube3a*^{m-/p+}) AS mouse to search for genes affected in the absence of *Ube3a*. We observed 64 differentially expressed transcripts (7 upregulated and 57 downregulated) showing more than 1.5-fold differences in expression ($P < 0.05$). Pathway analysis shows that these genes are implicated in three major networks associated with cell signaling, nervous system development and cell death. Using quantitative reverse-transcription PCR, we validated the differential expression of genes (*Fgf7*, *Gira1*, *Mc1r*, *Nr4a2*, *Slc5a7* and *Epha6*) that show functional relevance to AS phenotype. We also show that the protein level of melanocortin 1 receptor (*Mc1r*) and nuclear receptor subfamily 4, group A, member 2 (*Nr4a2*) in the AS mice cerebellum is decreased relative to that of the wild-type mice. Consistent with this finding, expression of small-interfering RNA that targets *Ube3a* in P19 cells caused downregulation of *Mc1r* and *Nr4a2*, whereas overexpression of *Ube3a* results in the upregulation of *Mc1r* and *Nr4a2*. These observations help in providing insights into the genesis of neurodevelopmental phenotype of AS and highlight specific areas for future research.

European Journal of Human Genetics (2010) 18, 1228–1235; doi:10.1038/ejhg.2010.95; published online 23 June 2010

Keywords: E6AP; neurological disorder; *Mc1r*; *Nr4a2*

INTRODUCTION

Angelman syndrome (AS, OMIM 105830) is a human neurogenetic disorder affecting approximately 1 in 10 000–40 000 newborns.^{1,2} AS patients show distinct dysmorphic facial features, inappropriate laughter, ataxia and motor dysfunction.³ Many patients also show seizures of variable magnitude, learning deficit and hypopigmentation.³ Molecular genetic studies show that AS is caused by the lack of functional *UBE3A* expression.⁴ *UBE3A* encodes the E6-AP ubiquitin ligase, and is found to be imprinted in a selected brain cell population such that only the maternal inherited allele is expressed.⁵ *UBE3A* functions mainly through targeting proteins for proteasomal degradation, and is also known to function as a coactivator for steroid hormone receptors.^{6,7}

In the brain neurons in which *UBE3A* is imprinted, it was found that *UBE3A* is localized in the nucleus, presynaptic and postsynaptic regions.^{6,8} *Ube3a*-deficient mice showed long-term potentiation impairment and abnormal dendritic spine number and morphology.^{8,9} Similarly, in *Drosophila*, either deficiency or overexpression of d*UBE3A* leads to reduced dendritic branching.¹⁰ These reports suggested that *UBE3A* may exert its effect locally in the synaptic region regulating dendritic spine development, synaptic plasticity and functions. Ubiquitination targets of *UBE3A*, such as p53, epithelial cell-transforming sequence 2 oncogene (*Ect2*) and tuberous sclerosis 2 (*TSC2*), and interacting partners, such as HSP70, have been identified.^{6,11–14} However, the role of *UBE3A* in the brain and how its deficiency can result in AS remain unclear.

To find out which genes are affected in the absence of functional *Ube3a* in the brain, we performed a genome-wide microarray

expression analysis on wild-type and *Ube3a*^{m-/p+} mice. We identified 64 genes showing greater than 1.5-fold differences in expression ($P < 0.05$) in the *Ube3a*^{m-/p+} mouse. Pathway analysis reveals that they are involved in three major networks, including cell signaling, nervous system development and cell death. Expression of functionally relevant candidates from each pathway was validated using quantitative reverse-transcription PCR (qRT-PCR). Among them, both melanocortin 1 receptor (*Mc1r*), which is shown to have a neuroprotective effect in the brain, and nuclear receptor subfamily 4, group A, member 2 (*Nr4a2*), which is critical for survival of dopamine neurons and whose expression can be induced by *Mc1r*, are downregulated.^{15–17} We have confirmed that the decline of *Mc1r* and *Nr4a2* at transcriptional level is reflected at the protein level in the *Ube3a*^{m-/p+} mouse. Using RNA interfering approach, we have further shown that shRNA-mediated knockdown of *Ube3a* in P19 cells leads to downregulation of *Mc1r* and *Nr4a2*. In contrast, overexpression of *Ube3a* in P19 cells results in the upregulation of *Mc1r* and *Nr4a2* mRNA levels. These results provide informative molecular insights on the pathogenesis of AS, as well as the functions of *Ube3a*.

MATERIALS AND METHODS

Ethics statement/mouse strains

All animal work was maintained, performed and approved by the School of Biological Sciences Animal Facility based on guidelines from the Institutional Animal Care and Use Committee. *Ube3a*^{m-/p+} mice were generated and confirmed using PCR as previously described.⁹

¹School of Biological Sciences, Nanyang Technological University, Singapore, Singapore

*Correspondence: Dr K-S Chen, School of Biological Sciences, Nanyang Technological University, 60 Nanyang Drive, Singapore 637551, Singapore.

Tel: +65 6316 2829; Fax: +65 6791 3856; E-mail: kschen@ntu.edu.sg

Received 8 February 2010; revised 26 April 2010; accepted 19 May 2010; published online 23 June 2010

Microarray sample preparation and hybridization

Cerebellum total RNA were extracted from 6-week-old female wild-type and *Ube3a^{m-/p+}* mice using Trizol reagents (Invitrogen Inc., Carlsbad, CA, USA) according to the manufacturer's protocol. Starting total RNA (1 µg) was used from each sample for the Affymetrix GeneChip Mouse Exon Array analysis. Samples were processed according to Affymetrix GeneChip Whole Transcript Sense Target Labeling Assay (Affymetrix Inc., Santa Clara, CA, USA).

Analysis and statistic

Four biological replicates from each of wild-type and *Ube3a^{m-/p+}* mice were included in the final analysis to detect differential gene expression derived from Partek Genomic Suite (Partek Inc., St Louis, MO, USA). The Affymetrix generated CEL files containing raw data were subjected to RMA normalization, background subtraction and summarization. One-way ANOVA was subsequently performed to detect *P*-values for the respective gene expression fold changes. The criteria for a gene to be considered differentially expressed were set at $P \leq 0.05$ and a minimal fold change of 1.5-fold. Gene ontology and network/pathway analyses were performed using Ingenuity Pathways Analysis software (Ingenuity System, Redwood City, CA, USA). Quality control analysis was performed using Affymetrix Expression Console software with reference to Affymetrix quality control white papers.

Semiquantitative reverse-transcription PCR

Total RNA (2 µg) from each sample was treated with RQ1 DNase (Promega, Madison, WI, USA) and then reverse-transcribed using Superscript (Invitrogen Inc.). Subsequently, 1 µl of the cDNA template generated was used for each PCR reaction using Faststart Taq Polymerase (Roche, Indianapolis, IN, USA), and cycling conditions were 95°C for 10 min, then 30–35 cycles of 30 s at 95°C, 30 s at 60°C and 30 s at 72°C, followed by a final extension of 10 min at 72°C.

qRT-PCR

A 25 µl reaction containing iTaq SYBR Green Supermix with ROX (Bio-Rad, Hercules, CA, USA) was prepared according to the manufacturer's instructions, and PCR-amplified using ABI 7500 System (Applied Biosystems, Carlsbad, CA, USA). Cycling conditions include 10 min at 50°C, 10 min at 95°C, then 45 cycles of 30 s at 95°C, 30 s at 60°C and 32 s at 72°C. The experiment was performed in three biological replicates. The C_T value for each gene was determined in the linear phase of the amplification for each gene, and normalized to C_T value of *G3pdh* to obtain the ΔC_T . The fold change for each gene was obtained using $2^{-(\text{mean wild-type } \Delta C_T - \text{mean } Ube3a^{m-/p+} \Delta C_T)}$. A simple *t*-test was performed on the ΔC_T for each gene to obtain a *P*-value for differential expression.

Western blot

Cerebellum from six-week-old female mouse was homogenized in lysis buffer (30 mM Tris, 7 M urea, 2 M thiourea, 4% CHAPS (pH 8.5), protease inhibitor). P19 cells were lysed in lysis buffer (0.1 M Tris-HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 2 mM MgCl₂, 1% Triton X-100, 15% glycerol, 2 mg/ml phenylmethylsulfonyl fluoride and protease inhibitor). Total protein (10 µg) was separated

in SDS-PAGE, and Western blotting was performed using primary anti-Ube3a (Bethyl Laboratories, Montgomery, TX, USA), anti-Mc1r and anti-Nr4a2 antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA), and detected by chemiluminescence horseradish-peroxidase-conjugated secondary antibody.

shRNA expressing vector construct

A 19-mer (5'-ctt-cgt-atg-gat-aac-aat-g-3') against exon 5 of *Ube3a* (GenBank accession number: NM_011668.2) was cloned into pSUPER.puro vector (Oligoengine, Seattle, WA, USA) for the shRNA-mediated *Ube3a* knockdown. The targeted exon 5 corresponds to the exon 2 that was deleted in the mouse previously described.⁹ This construct will be referred to as pUbe3aKD hereafter.

Ube3a overexpression vector construct

Ube3a coding region was amplified from p3003 pGEM E6-AP (Addgene, Cambridge, MA, USA) using forward primer: 5'-gat-cta-ggt-acc-tat-ggc-cac-agc-ttg-taa-aag-3' and reverse primer: 5'-act-gat-gga-tcc-tta-cag-cat-gcc-aaa-tcc-3'. The 2559 bp PCR product was then cloned into pcDNA/HisMaxB vector (Invitrogen Inc.) between the *KpnI* and *BamHI* restriction sites. To track the transfection/expression efficiency, we amplified a 1368 bp fragment containing the internal ribosomal entry site-eGFP fusion from pIGCN21 vector (NCI-Frederick, Frederick, MD, USA) using forward primer: 5'-gat-cta-gga-tcc-gcc-aag-cta-tcg-aat-tcc-gc-3' and reverse primer: 5'-act-gat-gcg-gcc-gct-tat-gca-gaa-ttc-gaa-gct-tga-gc-3' and cloned between the *BamHI* and *NotI* sites of the pcDNA/HisMaxB vector. This vector will be referred to as pUbe3aOE hereafter.

Cell culture and transfection

P19 cells were cultured in α -minimum essential medium supplemented with 7.5% bovine calf serum and 2.5% fetal bovine serum. P19 cells (4×10^5) were transfected with pUbe3aKD or pUbe3aOE in a six-well plate using Lipofectamine 2000 reagent (Invitrogen Inc.) according to the manufacturer's protocol. Cells were collected 24 h later.

RESULTS

Whole-genome microarray analysis

We are interested in identifying genes that are affected in the absence of functional *Ube3a*. Because *Ube3a* is expressed from the maternal inherited allele in the cerebellum,⁵ we checked for differential gene expression between wild-type and *Ube3a^{m-/p+}* mice. We performed microarray analysis using Affymetrix GeneChip Mouse Exon array on four biological replicates from each group. Genes are considered to be differentially expressed if they show a fold change of at least 1.5-fold and $P \leq 0.05$.

We analyzed the gene expression profiles between the two groups using the Core Probeset, which is based on highly confident supporting evidence from RefSeq and GenBank full-length mRNAs. This yielded a total of 64 differentially expressed genes (7 upregulated and 57 downregulated) that were statistically significant (Table 1).

Table 1 Microarray gene expression analysis (Core Probeset): wild-type (*Ube3a^{m+/p+}*) vs *Ube3a* knockout (*Ube3a^{m-/p+}*) mice

No.	Affymetrix transcript ID	NCBI accession no.	Gene symbol	Gene name	<i>P</i> -value	Fold change
<i>Upregulation in mutant</i>						
1	6880900	NM_008008	<i>Fgf7</i>	Fibroblast growth factor 7/	0.022	2.091
2	6927341	NM_080445	<i>B3gal6</i>	UDP-Gal:βGal β 1,3-galactosyltransferase	0.036	1.907
3	6817951	AK029771	<i>9330180L21Rik</i>	RIKEN cDNA 9330180L21	0.015	1.750
4	6985703	NM_026758	<i>Mphosph6</i>	M-phase phosphoprotein 6	0.039	1.701
5	6786954	AK085965	<i>2010316F05Rik</i>	RIKEN cDNA 2010316F05	0.027	1.587
6	6935555	NM_019647	<i>Rpl21</i>	Ribosomal protein L21	0.032	1.542
7	6935197	NM_001038703	<i>Gpr146</i>	G-protein-coupled receptor 146	0.035	1.541
<i>Downregulation in mutant</i>						
8	6992946	NM_178676	<i>Entpd3</i>	Ectonucleoside triphosphate diphosphohydrolase 3	0.008	-1.501
9	6976233	NM_080438	<i>Glr3</i>	Glycine receptor, α-3 subunit	0.045	-1.502

Table 1 (Continued)

No.	Affymetrix transcript ID	NCBI accession no.	Gene symbol	Gene name	P-value	Fold change
10	6967109	NM_013643	<i>Ptpn5</i>	Protein tyrosine phosphatase, nonreceptor type 5	0.002	-1.507
11	6963197	NM_007627	<i>Cckbr</i>	Cholecystokinin B receptor	0.012	-1.517
12	6786049	NM_172496	<i>Cobl</i>	Cordon-bleu	0.040	-1.531
13	6898010	NM_008604	<i>Mme</i>	Membrane metallo-endopeptidase	0.027	-1.532
14	6925872	NM_008154	<i>Gpr3</i>	G-protein-coupled receptor 3	0.029	-1.542
15	6846576	NM_007938	<i>Epha6</i>	Eph receptor A6	0.004	-1.555
16	6979704	NM_008559	<i>Mc1r</i>	Melanocortin 1 receptor	0.001	-1.556
17	6942379	NM_010717	<i>Limk1</i>	LIM-domain containing, protein kinase	0.043	-1.561
18	6870979	BC023699	<i>AI790298</i>	Expressed sequence AI790298	0.024	-1.566
19	6819928	NM_175498	<i>Pnma2</i>	Paraneoplastic antigen MA2	0.044	-1.575
20	6960931	NM_001033962	<i>Ube3a</i>	Ubiquitin protein ligase E3A	0.016	-1.579
21	6971996	NM_021302	<i>Stk32c</i>	Serine/threonine kinase 32C	0.029	-1.587
22	6764046	BC126965	<i>Pcp4l1</i>	Purkinje cell protein 4-like 1	0.029	-1.589
23	6819244	NM_009947	<i>Cpne6</i>	Copine VI	0.014	-1.601
24	6873187	NM_145123	<i>Crtac1</i>	Cartilage acidic protein 1	0.002	-1.613
25	6966324	NM_010758	<i>Mag</i>	Myelin-associated glycoprotein	0.038	-1.615
26	6833516	NM_008800	<i>Pde1b</i>	Phosphodiesterase 1B, Ca ²⁺ -calmodulin dependent	0.049	-1.620
27	6930606	NM_178804	<i>Slit2</i>	Slit homologue 2 (<i>Drosophila</i>)	0.034	-1.622
28	6820282	NM_172812	<i>Htr2a</i>	5-Hydroxytryptamine (serotonin) receptor 2A	0.010	-1.625
29	6760417	NM_021306	<i>Ecel1</i>	Endothelin-converting enzyme-like 1	0.004	-1.631
30	6933072	NM_009263	<i>Spp1</i>	Secreted phosphoprotein 1	0.047	-1.633
31	6994790	NM_178737	<i>AW551984</i>	Expressed sequence AW551984	0.025	-1.634
32	6982725	BC111102	<i>4930431L04Rik</i>	RIKEN cDNA 4930431L04 gene	0.032	-1.636
33	6762197	NM_008795	<i>Pctk3</i>	PCTAIRE-motif protein kinase 3	0.029	-1.638
34	6805200	NM_145451	<i>Gpx6</i>	Glutathione peroxidase 6	0.026	-1.639
35	6832276	NM_172610	<i>Mpped1</i>	Metallophosphoesterase domain containing 1	0.017	-1.658
36	6947131	NM_028880	<i>Lrrtm1</i>	Leucine-rich repeat transmembrane neuronal 1	0.044	-1.669
37	6810961	NM_033269	<i>Chrm3</i>	Cholinergic receptor, muscarinic 3	0.020	-1.679
38	6864813	NM_011898	<i>Spry4</i>	Sprouty homologue 4 (<i>Drosophila</i>)	0.022	-1.687
39	6750314	NM_177164	<i>A830006F12Rik</i>	RIKEN cDNA A830006F12 gene	0.005	-1.698
40	6931001	NM_018764	<i>Pcdh7</i>	Protocadherin 7	0.003	-1.725
41	6856133	NM_022025	<i>Slc5a7</i>	Solute carrier family 5 (choline transporter)	0.039	-1.738
42	6854467	XM_989487	<i>LOC671855</i>	Similar to Rho GDP-dissociation inhibitor 3	0.005	-1.753
43	6901119	NM_022565	<i>Ndst4</i>	N-Deacetylase/N-sulfotransferase (heparin glucosaminyl) 4	0.042	-1.762
44	6808279	NM_013628	<i>Pcsk1</i>	Protein convertase subtilisin/kexin type 1	0.033	-1.765
45	6854844	NM_010831	<i>Snf1lk</i>	SNF1-like kinase	0.015	-1.775
46	6801807	NM_172805	<i>Kcnh5</i>	Potassium voltage-gated channel, subfamily H (eag-related)	0.007	-1.787
47	6803891	NM_178915	<i>Tmem179</i>	Transmembrane protein 179	0.005	-1.788
48	6988976	NM_010077	<i>Drd2</i>	Dopamine receptor 2	0.017	-1.794
49	6815027	NM_009027	<i>Rasgrf2</i>	RAS protein-specific guanine nucleotide-releasing factor 2	0.044	-1.815
50	6931355	NM_011670	<i>Uchl1</i>	Ubiquitin C-terminal hydrolase L1	0.041	-1.822
51	6906620	NM_011839	<i>Mab21l2</i>	Mab-21-like 2 (<i>C. elegans</i>)	0.031	-1.979
52	6862816	NM_144946	<i>Neto1</i>	Neuropilin (NRP) and tolloid (TLL)-like 1	0.016	-1.981
53	6785684	NM_010904	<i>Nefh</i>	Neurofilament, heavy polypeptide	0.043	-2.088
54	6894253	NM_015730	<i>Chrna4</i>	Cholinergic receptor, nicotinic, α -polypeptide 4	0.004	-2.093
55	6886908	NM_013613	<i>Nr4a2</i>	Nuclear receptor subfamily 4, group A, member 2	0.028	-2.148
56	6844649	NM_009215	<i>Sst</i>	Somatostatin	0.041	-2.211
57	6796691	NM_010234	<i>Fos</i>	FBJ osteosarcoma oncogene	0.015	-2.242
58	6889978	NM_010825	<i>Mrg1</i>	Myeloid ecotropic viral integration site-related gene 1	0.023	-2.334
59	6871062	NM_153553	<i>Npas4</i>	Neuronal PAS domain protein 4	0.012	-2.479
60	6967593	NM_176942	<i>Gabra5</i>	γ -Aminobutyric acid (GABA-A) receptor	0.017	-2.548
61	6943974	NM_009311	<i>Tac1</i>	Tachykinin 1	0.013	-2.615
62	6833311	NM_010444	<i>Nr4a1</i>	Nuclear receptor subfamily 4, group A, member 1	0.016	-2.741
63	6788423	NM_020492	<i>Glr1</i>	Glycine receptor, α -1 subunit	0.031	-4.946
64	6881459	NM_029530	<i>6330527006Rik</i>	RIKEN cDNA 6330527006 gene	0.010	-6.616

Differentially expressed genes with a fold change ≥ 1.5 ($P \leq 0.05$) from *Ube3a*^{fl/fl} mice compared with the wild-type littermates. List is shown in the order of the most upregulated, to the most downregulated gene (as shown by '-' sign).

The most heavily represented downregulated genes in the *Ube3a*^{m-/p+} mice appear to encode receptors for neurogenic functions, such as neurotransmitter receptors (eg *Glra1/3*, *Chrna4* and *Drd2*). Another substantial group of genes that were downregulated involves transcription regulation, functioning in neurogenesis and other physiological aspects (eg *Mc1r*, *Nr4a2* and *Npas*).

Pathway analysis

Pathway analysis shows that the differentially expressed genes are implicated in three major pathways/networks including cell signaling, nervous system development and cell death. Fifteen genes are involved in the first network associated with cell signaling (Figure 1a), including *Fgf7* and *Nr4a2*. In the brain, the orphan receptor *Nr4a2* supports dopaminergic neurons to survive and differentiate.¹⁵ Twelve genes are associated with the nervous system development and functions (Figure 1b). Among them are *Epha6*, a tyrosine kinase receptor important for axon guidance, as well as *Slc5a7*, which encodes choline transporter responsible for proper choline uptake along the synapse.^{18,19} Eleven genes are associated with cellular development/death (Figure 1c). Among them, downregulation of *Mc1r* and downregulation of *Glra1* are two examples that show functional relevance to AS.

Differential expression validation

We have validated and confirmed the differential expression status of two genes per network described above, using semiquantitative reverse-transcription PCR (Figure 2a) and qRT-PCR in biological triplicates (Figure 2b). These validated genes (ie *Fgf7*, *Glra1*, *Mc1r*, *Nr4a2*, *Slc5a7* and *Epha6*) were chosen because their functions are relevant to the AS phenotype.

A recent report shows that *Mc1r* signaling induces the expression of *Nr4a2*.¹⁷ Because both mRNAs are downregulated in the AS mice, we extended our differential expression analysis to the protein level for these two genes. To determine if downregulation of *Mc1r* and *Nr4a2* can be reflected at the protein levels, we performed Western blot comparing cerebellum total protein extract from wild-type and *Ube3a*^{m-/p+} mice. We found that both *Mc1r* (Figure 2c) and *Nr4a2* proteins (Figure 2d), like its relative transcript, are downregulated in the AS mouse.

Ube3a knockdown in P19 cell line

We were interested in finding out if knockdown of *Ube3a* in P19 cell line will lead to downregulation of *Mc1r* and *Nr4a2* similar to what we have observed in the *Ube3a*^{m-/p+} mice. It is possible that the constitutive loss of *Ube3a* activity during mouse development may result in adaptive change in gene expression (to cope with loss of *Ube3a* activity), and thus many of the changes observed in the transcriptional level may represent indirect, rather than direct, consequences on loss of *Ube3a* activity.

To address this problem, we have generated an RNAi system with target sequence against *Ube3a*, in which immediate effect of loss of *Ube3a* activity on respective genes/proteins can be evaluated. The P19 cells transfected with shRNA expression plasmid show downregulation of *Ube3a* at both transcription and protein levels. There is a two-fold reduction in the *Ube3a* mRNA level after knockdown (Figure 3a and b). Consistent with this result, *Ube3a* protein in P19 cells was reduced after transfection with the *Ube3a* shRNA expression plasmid as determined by Western blot analysis (Figure 3c). We then check for relative transcript expression of *Mc1r* and *Nr4a2* in the *Ube3a* knockdown and control cells. Semiquantitative reverse-transcription PCR (Figure 3a) and biological triplicates of qRT-PCR (Figure 3b) show

that *Mc1r* and *Nr4a2* mRNA levels decreased by 8.6- and 5.3-fold, respectively, in the *Ube3a* knockdown cells. These results suggest that functional *Ube3a* is perhaps required for *Mc1r* and *Nr4a2* gene expression.

Overexpression of *Ube3a* in P19 cell line

Because downregulation of *Mc1r* and *Nr4a2* is observed in the *Ube3a*^{m-/p+} mice and *Ube3a* knockdown P19 cells, we were interested in determining if the levels of *Mc1r* and *Nr4a2* will be affected when *Ube3a* is overexpressed. We constructed an *Ube3a* expression vector, pUbe3aOE, and transfection of P19 cells with this plasmid resulted in higher level of *Ube3a* expression as determined by Western blot (Figure 4a). Subsequently, the mRNA level of *Mc1r* and *Nr4a2* was determined using qRT-PCR. We observed a 5.9- and 10.9-fold increase in the mRNA level of *Mc1r* and *Nr4a2*, respectively (Figure 4b).

DISCUSSION

Lack of functional maternal *Ube3a* expression in imprinted brain tissue can result in the accumulation of target proteins that are meant to be degraded through the ubiquitin proteasomal system, as well as dysregulation of genes expression due to the lack of the coactivation function of *Ube3a*. We used a genome-wide approach to detect differential genes expression between wild-type and *Ube3a*^{m-/p+} mice cerebellum. The mouse cerebellum was used because previous studies show that *Ube3a* is imprinted in the cerebellum and electrophysiology recording reveal abnormal oscillatory activity in the AS mice.^{5,20} In addition, the cerebellum controls motor movements, which most AS patient lack.³ P19 cells were used to investigate the knockdown/overexpression effect of *Ube3a* because these pluripotent embryonic cells can be induced to differentiate into neurons.²¹ In addition, neurons and skin are derived from the same lineage progenitor cells.²²

In this study, we have shown that *Mc1r* is downregulated in AS mice at mRNA and protein levels. *Mc1r*, a G-protein-coupled receptor, is widely studied in peripheral tissues, such as the skin, for its regulation of pigment production.²³ *OCA2*, an autosomal recessive gene that is responsible for type 2 oculocutaneous albinism, is currently attributed toward the hypopigmentation phenotype seen in type I (deletion) AS patients as it lies within the AS deletion region along 15q11–q13.^{24,25} However, this does not explain why other AS patients with *UBE3A* mutations, imprinting defect along 15q11–q13 or paternal uniparental disomy (type II–IV), which have intact *OCA2*, still show to a certain extent, the hypopigmentation phenotype.²⁶ Gene expression in AS mouse cerebellum used in this study may be different from gene expression in other tissues such as the skin, even though neurons and skin are derived from the same lineage cells.²² However it would be interesting to determine if *Ube3a* mutation also causes downregulation of *Mc1r* in the skin, resulting in the perturbation of normal pigment production seen in type II–IV patients. Co-deletion of *OCA2* and *UBE3A*, which results in the decrease of *Mc1r*, observed in type I deletion patients could perhaps lead to a synergistic effect, resulting in the stable and full-blown hypopigmentation phenotype.

In the brain, *Mc1r* was shown to prevent inflammation, as well as to provide a neuroprotective effect on the brain cell population.¹⁶ On top of that, a recent report shows that *Mc1r* signaling rapidly, yet transiently, induces transcription of the *Nr4a* subfamily receptors.¹⁷ The *Nr4a* subfamily receptors, *Nr4a1/Nurr77*, *Nr4a2/Nurr1*, and *Nr4a3/NOR-1* are orphan receptors, well known for their close ligand-binding sites.²⁷ We have shown that in the absence of maternal *Ube3a* in the brain, *Nr4a2* transcript is reduced. Taken together, it is




Figure 1 Pathway analysis on differentially expressed genes. (a) Network 1 is associated with cell signaling and involves 15 of our reported differentially expressed genes (in bold). Representative genes such as *Fgf7* and *Nr4a2* are qRT-PCR validated, which are up- and downregulated in the *Ube3a^{m-/-}* mice, respectively. (b) Network 2 is associated with nervous system development and involves 12 of our reported microarray hits. *Epha6* and *Slc5a7* in this network are qRT-PCR validated showing both downregulations in the *Ube3a^{m-/-}* mice. (c) Network 3 is associated with cell death and involves 11 genes, such as *Glr1* and *Mc1r*. Both are down-regulated in the *Ube3a^{m-/-}* mice and validated using qRT-PCR.




Figure 2 Semiquantitative reverse-transcription PCR, qRT-PCR and Western blot validation confirming on a selection of differentially expressed genes identified by microarray. **(a)** Semiquantitative reverse-transcription PCR validation: *Fgf7* is upregulated in *Ube3a*^{m-/p+} mice, whereas the rest of the genes, including *Glra1*, *Mc1r*, *Nr4a2*, *Epha6* and *Slc5a7*, are confirmed to be downregulated. NTC: no template control. **(b)** qRT-PCR validation showing the normalized mean fold change from the biological triplicates. The fold change is calculated using $2^{-(\text{mean wild-type } \Delta\text{CT} - \text{mean } Ube3a(m-/p+) \Delta\text{CT})}$; '+' and '-' represent upregulation and downregulation of transcript, respectively; * $P < 0.05$. **(c and d)** Total protein (10 μg) extracted from mouse cerebellum was analyzed by SDS-PAGE using 6% acrylamide gel. Western blot analyses using antibody against *Mc1r* and *Nr4a2* show that the 35 kDa *Mc1r* (**c**) and the 66 kDa *Nr4a2* (**d**) proteins, respectively, are downregulated in the *Ube3a*^{m-/p+} mice. β -Actin is used as endogenous internal control in the Western blot analyses.

conceivable that *Ube3a* might have a direct role in stimulating the synthesis of *Mc1r*, which in turn, regulates *Nr4a2* gene expression.

Reducing the expression of *Nr4a2* in the brain might explain certain AS phenotype, including poor learning/memory, and motor incoordination. *Nr4a2* knockdown in rat hippocampus was reported to affect spatial discrimination, learning and memory.²⁸ In the AS mouse model, where *Nr4a2* is downregulated, the mice show severe long-term potentiation and learning impairment.⁹ In contrast, *Nr4a2* mRNA expression was found to be increased during learning in the rat models.²⁹ In a recent report, *Nr4a2* has been shown to interact with Wnt signaling via β -catenin in the establishment and development of the nervous system.³⁰ More importantly, *Nr4a2* was reported to be critical for induction and survival of dopaminergic neurons.¹⁵ *Nr4a2*^{+/-} mice appear normal at birth, but show motor abnormality as a result

of reduce numbers of dopaminergic neurons.³¹ Hence, the motor dysfunction observed in AS patients as a result of loss of maternal *Ube3a* could possibly be related to the decrease levels of *Nr4a2*, which mediates the induction and survival of dopaminergic neurons.¹⁵

In addition, we have identified many neurotransmitter receptors that are differentially expressed in the AS mice, including glycine receptor (*Glra1*), γ -aminobutyric acid receptor (*Gabra5*) and cholinergic receptor (*Chrna4*). The localization of *UBE3A*^{YFP} fusion gene at the pre/postsynaptic regions of cultured hippocampal neurons led to the speculation that *UBE3A* may directly regulate the development and/or synaptic functions.⁸ Downregulation of neurotransmitter receptors could affect proper neuro-signal transduction and normal neuronal and motor functions. For example, mutations in *Glra1* result




Figure 3 Validation of downregulation of *Mc1r* and *Nr4a2* by shRNA-mediated knockdown of *Ube3a* in P19 cells. (a) Semi-quantitative reverse-transcription PCR showing the downexpression of *Ube3a*, *Mc1r* and *Nr4a2* transcript in the *Ube3a* shRNA-transfected cells. NTC: no template control. (b) Biological triplicates of qRT-PCR analyses showing the normalized mean fold change. ‘-’ represents a downregulation in the *Ube3a* shRNA-transfected cells; * $P < 0.05$. (c) Total protein (10 μ g) extracted from the *Ube3a* shRNA-transfected and control P19 cells was analyzed by SDS-PAGE using 6% acrylamide gel. Western blot analyses using antibody against *Ube3a* show the knockdown of the 95 kDa *Ube3a* on transfection with the *Ube3a* shRNA plasmid (pUbe3aKD). Total protein extracted from wild-type and the *Ube3a*^{m-/p+} mice cerebellum was used as positive and negative control in the same Western blot analyses. β -Actin is used as endogenous internal control in the Western blot analysis.




Figure 4 *Ube3a* overexpression results in an upregulation of *Mc1r* and *Nr4a2*. (a) Total protein (10 μ g) extracted from P19 cells transfected with the *Ube3a* expression plasmid (pUbe3aOE) and control cells was analyzed by SDS-PAGE using 6% acrylamide gel. Western blot analyses using antibody against *Ube3a* show the increase protein level of the 95 kDa *Ube3a* on overexpression of *Ube3a*. β -Actin is used as endogenous internal control in the Western blot analysis. (b) Biological triplicates of qRT-PCR analyses showing the normalized mean fold change of *Mc1r* and *Nr4a2* on *Ube3a* overexpression in P19 cells. ‘+’ represents an upregulation in the *Ube3a*-overexpressed cells; * $P < 0.05$.

in hyperekplexia, where patients show 'drop seizure' phenotype.³² These symptoms show overlapping phenotype to the AS, creating a possibility that the cause of some of the AS phenotype, such as seizure, might be associated with lack of *Gbra1* expression. The reason why *Gabra5* is downregulated in *Ube3a*-deficient mouse is unclear. Besides direct or indirect mechanisms involving the loss of the coactivator and/or ubiquitin ligase functions of Ube3a, it is possible that a chromatin structure alteration, or the loss of a positive regulatory element caused by *Ube3a* knockout may lead to downregulation of *Gabra5*, given that *Gabra5* is located adjacent to *Ube3a* in mouse (7c) and human (15q12). A similar effect is seen for upregulation of *Irak1* in the *Mecp2*-deficient mouse model.^{33,34}

Altogether, we had performed a genome-wide gene expression profiling of *Ube3a*^{m-/p+} mice with the intention of identifying genes that are affected in the absence of functional Ube3a. We have observed 64 genes that are differentially expressed in the AS mice. These genes fit into three major networks associated with cell signaling, nervous system development and cell death. We validated the expression of six representative genes (*Fgf7*, *Gbra1*, *Mcl1*, *Nr4a2*, *Epha6*, and *Slc5a7*) using qRT-PCR. Using an shRNA knockdown system, we have shown that *Ube3a* knockdown causes downregulation of *Mcl1* and *Nr4a2* in the embryonic P19 cell, whereas overexpression of Ube3a results in upregulation of *Mcl1* and *Nr4a2*, suggesting that Ube3a is involved in regulating their expression. These results can provide a step forward toward a better understanding of AS development and narrows down some critical genes affected in the event of *Ube3a* mutations that might contribute to the onset of the disease.

CONFLICT OF INTEREST

The authors declare no conflict of interest.

ACKNOWLEDGEMENTS

This work was supported by the Academic Research Fund (M52080025) from Nanyang Technological University awarded to Ken-Shiung Chen.

- 1 Clayton-Smith J, Driscoll DJ, Waters MF *et al*: Difference in methylation patterns within the D15s9 region of chromosome 15q11–13 in 1st cousins with Angelman syndrome and Prader–Willi syndrome. *Am J Med Genet* 1993; **47**: 683–686.
- 2 Thomson AK, Glasson EJ, Bittles AH: A long-term population-based clinical and morbidity profile of Angelman syndrome in Western Australia: 1953–2003. *Disabil Rehabil* 2006; **28**: 299–305.
- 3 Williams CA, Beaudet AL, Clayton-Smith J *et al*: Angelman syndrome 2005: updated consensus for diagnostic criteria. *Am J Med Genet A* 2006; **140A**: 413–418.
- 4 Kishino T, Lalonde M, Wagstaff J: UBE3A/E6-AP mutations cause Angelman syndrome. *Nat Genet* 1997; **15**: 70–73.
- 5 Albrecht U, Sutcliffe JS, Cattanach BM *et al*: Imprinted expression of the murine Angelman syndrome gene, Ube3a, in hippocampal and Purkinje neurons. *Nat Genet* 1997; **17**: 75–78.
- 6 Scheffner M, Huibregtse JM, Vierstra RD, Howley PM: The Hsp-16 E6 and E6-AP complex functions as a ubiquitin-protein ligase in the ubiquitination of P53. *Cell* 1993; **75**: 495–505.
- 7 Nawaz Z, Lonard DH, Smith CL *et al*: The Angelman syndrome-associated protein, E6-AP, is a coactivator for the nuclear hormone receptor superfamily. *Mol Cell Biol* 1999; **19**: 1182–1189.
- 8 Dindot SV, Antalffy BA, Bhattacharjee MB, Beaudet AL: The Angelman syndrome ubiquitin ligase localizes to the synapse and nucleus, and maternal deficiency results in abnormal dendritic spine morphology. *Hum Mol Genet* 2008; **17**: 111–118.
- 9 Jiang YH, Armstrong D, Albrecht U *et al*: Mutation of the Angelman ubiquitin ligase in mice causes increased cytoplasmic p53 and deficits of contextual learning and long-term potentiation. *Neuron* 1998; **21**: 799–811.
- 10 Lu YB, Wang F, Li Y, Ferris J, Lee JA, Gao FB: The *Drosophila* homologue of the Angelman syndrome ubiquitin ligase regulates the formation of terminal dendritic branches. *Hum Mol Genet* 2009; **18**: 454–462.
- 11 Huibregtse JM, Scheffner M, Howley PM: Localization of the E6-AP regions that direct human papillomavirus E6 binding, association with P53, and ubiquitination of associated proteins. *Mol Cell Biol* 1993; **13**: 4918–4927.
- 12 Reiter LT, Seagroves TN, Bowers M, Bier E: Expression of the Rho-GEF Pbl/ECT2 is regulated by the UBE3A E3 ubiquitin ligase. *Hum Mol Genet* 2006; **15**: 2825–2835.
- 13 Zheng L, Ding HR, Lu ZM *et al*: E3 ubiquitin ligase E6AP-mediated TSC2 turnover in the presence and absence of HPV16 E6. *Genes Cells* 2008; **13**: 285–294.
- 14 Mishra A, Godavarthi SK, Maheshwari M, Goswami A, Jana NR: The ubiquitin ligase E6-AP is induced and recruited to aggresomes in response to proteasome inhibition and may be involved in the ubiquitination of Hsp70-bound misfolded proteins. *J Biol Chem* 2009; **284**: 10537–10545.
- 15 Saucedo-Cardenas O, Quintana-Hau JD, Le WD *et al*: Nurr1 is essential for the induction of the dopaminergic phenotype and the survival of ventral mesencephalic late dopaminergic precursor neurons. *Proc Natl Acad Sci USA* 1998; **95**: 4013–4018.
- 16 Catania A: Neuroprotective actions of melanocortins: a therapeutic opportunity. *Trends Neurosci* 2008; **31**: 353–360.
- 17 Smith AG, Luk N, Newton RA, Roberts DW, Sturm RA, Muscat GEO: Melanocortin-1 receptor signaling markedly induces the expression of the NR4A nuclear receptor subgroup in melanocytic cells. *J Biol Chem* 2008; **283**: 12564–12570.
- 18 Apparsundaram S, Ferguson SM, George AL, Blakely RD: Molecular cloning of a human, hemicholinium-3-sensitive choline transporter. *Biochem Biophys Res Commun* 2000; **276**: 862–867.
- 19 Yue Y, Chen ZY, Gale NW *et al*: Mistargeting hippocampal axons by expression of a truncated Eph receptor. *Proc Natl Acad Sci USA* 2002; **99**: 10777–10782.
- 20 Cheron G, Servais L, Wagstaff J, Dan B: Fast cerebellar oscillation associated with ataxia in a mouse model of Angelman syndrome. *Neuroscience* 2005; **130**: 631–637.
- 21 Jonesvilleneuve EMV, McBurney MW, Rogers KA, Kalnins VI: Retinoic acid induces embryonal carcinoma cells to differentiate into neurons and glial cells. *J Cell Biol* 1982; **94**: 253–262.
- 22 Baroffio A, Dupin E, Ledouarin NM: Common precursors for neural and mesodermal derivatives in the cephalic neural crest. *Development* 1991; **112**: 301–305.
- 23 Luger TA, Paus R, Lipton JM, Slominski AT (eds): The melanocortin-1 receptor and human pigmentation. *Conference on Cutaneous Neuroimmunomodulation – The Proopiomelanocortin System*; 11–13 Sep; Munster, Germany.
- 24 Oetting WS, King RA: Molecular basis of albinism: mutations and polymorphisms of pigmentation genes associated with albinism. *Hum Mutat* 1999; **13**: 99–115.
- 25 Fridman C, Hosomi N, Varela MC, Souza AH, Fukai K, Koiffmann CP: Angelman syndrome associated with oculocutaneous albinism due to an intragenic deletion of the P gene. *Am J Med Genet A* 2003; **119A**: 180–183.
- 26 Lossie AC, Whitney MM, Amidon D *et al*: Distinct phenotypes distinguish the molecular classes of Angelman syndrome. *J Med Genet* 2001; **38**: 834–845.
- 27 Maxwell MA, Muscat GE: The NR4A subgroup: immediate early response genes with pleiotropic physiological roles. *Nucl Recept Signal* 2006; **4**: e002.
- 28 Colon-Cesario WI, Martinez-Montemayor MM, Morales S *et al*: Knockdown of Nurr1 in the rat hippocampus: implications to spatial discrimination learning and memory. *Learn Mem* 2006; **13**: 734–744.
- 29 de Ortiz SP, Maldonado-Vlaar CS, Carrasquillo Y: Hippocampal expression of the orphan nuclear receptor gene *hzf-3/nurr1* during spatial discrimination learning. *Neurobiol Learn Mem* 2000; **74**: 161–178.
- 30 Kitagawa H, Ray WJ, Glantschnig H *et al*: A regulatory circuit mediating convergence between Nurr1 transcriptional regulation and Wnt signaling. *Mol Cell Biol* 2007; **27**: 7486–7496.
- 31 Jiang CT, Wan XH, He Y, Pan TH, Jankovic J, Le WD: Age-dependent dopaminergic dysfunction in Nurr1 knockout mice. *Exp Neurol* 2005; **191**: 154–162.
- 32 Kirstein L, Silfverskiold BP: A family with emotionally precipitated drop seizures. *Acta Psychiatr Neurol* 1958; **33**: 471–476.
- 33 Chahrouh M, Jung SY, Shaw C *et al*: MeCP2, a key contributor to neurological disease, activates and represses transcription. *Science* 2008; **320**: 1224–1229.
- 34 Urduingio RG, Lopez-Serra L, Lopez-Nieva P *et al*: *Mecp2*-null mice provide new neuronal targets for Rett syndrome. *PLoS One* 2008; **3**: e3669.